Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Simonson PD, Wu Y, Wu D, Fromm JR, Lee AY. De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning. Am J Clin Pathol. 2021.

Wangsiricharoen S, Larman TC, Wakely PE, Siddiqui MT, Ali SZ. Cytopathology of extra-renal perivascular epithelioid cell tumor (PEComa): a series of 7 cases and review of the literature. J Am Soc Cytopathol. 2021;10(2):175-186.

Yang HS, Shemesh A, Li J, Xie T, Apple FS, Williams JA, et al. No increase in the incidence of cardiac troponin I concentration above the 99th percentile by Siemens Centaur high-sensitivity compared to the contemporary assay. Clin Biochem. 2021;89:77-80.

Heidarian A, Das KK, Mino-Kenudson M, Del Castillo CF, Pitman MB. Cytology adds value to monoclonal antibody Das-1 testing for detection of high-risk pancreatic cysts. J Am Soc Cytopathol. 2021;10(3):249-254.

Vega F, Amador C, Chadburn A, Hsi ED, Slack G, L Medeiros J, et al. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol. 2021.

Chan A, Carniello JV, Gao Q, Sigler A, Baik J, Roshal M, et al. Role of Flow Cytometric Immunophenotyping for Classic Hodgkin Lymphoma in Small Biopsy and Cytology Specimens. Arch Pathol Lab Med. 2021.

Karafin MS, Becker JL, Berg M, DeSimone RA, Draper NL, Hudgins J, et al. Heterogeneity in Approaches for Switching From Universal to Patient ABO Type-Specific Blood Components During Massive Hemorrhage: An International Survey and Review of the Literature. Arch Pathol Lab Med. 2021.

Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137(24):3378-3389.

Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al. Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Adv Mater. 2021:e2100096.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.